Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Invectys, Inc appoints Biopharma Veteran, Praveen Tyle, PhD as President & CEO
Invectys, Inc.May 4, 2021 GMT
Houston, TX, USA, May 04, 2021 (GLOBE NEWSWIRE) Invectys, Inc., a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products for cancer patients, today announced the appointment of Praveen Tyle, PhD, as President & CEO and election to its Board of Directors. Dr. Tyle brings over 35 years of experience in both large and small pharma and biotech companies, most recently serving as Executive V.P. for Research and Development of the public company, Lexicon Pharmaceuticals, Inc. Earlier, Dr. Tyle served as the Corporate Senior Vice President and Chief Scientific Officer of Bausch and Lomb and then as Senior Vice President and Global Head of Business Development and R&D at Novartis OTC. Subsequently, Dr. Tyle joined
Houston
Texas
United-states
Paris
France-general
France
Pasteur-institute
Shannon-fairbanks
Cary-mcnair
Virginie-leplat
Research-initiative-of-texas
Fairbanks-investment-fund-holdings